How do I interpret my Gleason score or Ki-67 for Lung Cancer

I appreciate your question, but I want to clarify something important: Gleason scores and Ki-67 are not typically used to evaluate lung cancer.

Let me explain what these are and why they don't apply to your situation:

Gleason Score

The Gleason score is a grading system specifically for prostate cancer, not lung cancer. It measures how abnormal prostate cancer cells look under a microscope. Since you have lung cancer, your pathology report wouldn't include a Gleason score.

Ki-67

Ki-67 is a proliferation marker (a measure of how quickly cells are dividing). While Ki-67 can occasionally be measured in lung cancer tissue, it's not a standard part of routine lung cancer evaluation and isn't typically used to guide treatment decisions the way it is in some other cancers.

What DOES Matter for Lung Cancer

Instead, your lung cancer evaluation focuses on different factors:

• Histology (cell type): Small cell lung cancer (SCLC) vs. non-small cell lung cancer (NSCLC)
• Stage: How far the cancer has spread (Stage I-IV)
• Biomarkers like:
  • PD-L1 expression (immune checkpoint marker)
  • EGFR mutations (genetic changes in tumor cells)
  • ALK rearrangements (another genetic change)
  • KRAS mutations
  • Tumor mutational burden (TMB)

According to NCCN Lung Cancer Guidelines, these biomarkers help determine which targeted therapies or immunotherapies might work best for your specific cancer.

Questions to Ask Your Team

1. What is my lung cancer histology (cell type)?
2. What stage is my cancer?
3. What biomarkers were tested on my tumor, and what do the results show?
4. How do my specific biomarkers influence treatment options?

If you have a pathology report from your lung cancer diagnosis, I'd be happy to help you understand what is included in it!

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.